Pharmacogenetics of antidepressant and mood-stabilizing drugs: A review of candidate-gene studies and future research directions

International Journal of Neuropsychopharmacology

Volumn 5, Issue 3, 2002, Pages 255-275

  Lerer, Bernard ^a   Macciardi, Fabio ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Antidepressants; Lithium; Molecular genetics; Mood stabilizers; Pharmacogenetics

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; FLUVOXAMINE; LITHIUM; MIRTAZAPINE; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PINDOLOL; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANALYTIC METHOD; CASE CONTROL STUDY; CLINICAL TRIAL; DEPRESSION; DNA DETERMINATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG RESEARCH; DRUG RESPONSE; DRUG TARGETING; EXON; GENE; GENE FUNCTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; HUMAN; INDIVIDUALIZATION; INTERMETHOD COMPARISON; INTRON; LINKAGE ANALYSIS; MANIA; MANIC DEPRESSIVE PSYCHOSIS; MEDICAL LITERATURE; MEDLINE; METHODOLOGY; PHARMACOGENETICS; POPULATION STRUCTURE; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PSYCHOPHARMACOTHERAPY; REVIEW; VARIABLE NUMBER OF TANDEM REPEAT;

AFFECT; ANIMALS; ANTIDEPRESSIVE AGENTS; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER; GENOME; HUMANS; LITHIUM; MOOD DISORDERS; PHARMACOGENETICS; RESEARCH DESIGN;

EID: 0036734874     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145702002936     Document Type: Review

References (134)

1. Alda M (1999). Pharmacogenetics of lithium response in bipolar disorder. Journal of Psychiatry and Neuroscience 24, 154-158.
2. Alda M (2002). Genetic factors and response to prophylactic treatment in bipolar disorder. In: Lerer B (Ed.), Pharmacogenetics of Psychotropic Drugs. Cambridge: Cambridge University Press.
3. Alda M, Grof E, Cavazzoni P, Duffy A, Martin R, Ravindran L, Grof P (1997). Autosomal recessive inheritance of affective disorders in families of responders to lithium prophylaxis. Journal of Affective Disorders 44, 153-157.
4. Alda M, Grof P, Grof E, Zvolsky P, Walsh M (1994). Mode of inheritance in families of patients with lithium-responsive affective disorders. Acta Psychiatrica Scandinavica 90, 304-310.
5. Alda M, Turecki G, Grof P, Cavazzoni P, Duffy A, Grof E, Ahrens B, Berghofer A, Muller-Oerlinghausen B, Dvorakova M, Libigerova E, Vojtechovsky M, Zvolsky P, Nilsson A, Prochazka H, Licht RW, Rasmussen NA, Schou M, Vestergaard P, Holzinger A, Schumann C, Thau K, Rouleau GA (2000). Association and linkage analyses of CRH and PENK genes in bipolar disorder responsive to lithium: a collaborative IGSLI study. American Journal of Medical Genetics (Neuropsychiatric Genetics) 96, 178-181.
6. Anderson IM (1998). SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depression and Anxiety 7, 11-17.
7. Angst J (1961). A clinical analysis of the effects of tofranil in depression. Longitudinal and follow-up studies. Treatment of blood relations. Psychopharmacologia 2, 381-407.
8. Angst J (1964). Antidepressive effect and genetic factors. Arzneimittelforschung 14, 496-500.
9. Baghai TC, Schule C, Zwanzger P, Minov C, Schwarz MJ, de Jongs S, Rupprecht R, Bondy B (2001). Possible influence of the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene on therapeutic outcome in affective disorders. Molecular Psychiatry 6, 258-259.
10. Benedetti F, Serretti A, Colombo C, Campori E, Barbini B, Di Bella D, Smeraldi E (1999). Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression. American Journal of Psychiatry 156, 1450-1452.
11. Bellivier F, Leboyer M, Courtet P, Buresi C, Beaufils B, Samolyk D, Allilaire JF, Feingold J, Mallet J, Malafosse A (1998). Association between the tryptophan hydroxylase gene and manic-depressive illness. Archives of General Psychiatry 55, 33-37.
12. Bennett PJ, McMahon WM, Watabe J, Achilles J, Bacon M, Coon H, Grey T, Keller T, Tate D, Tcaciuc I, Workman J, Gray D (2000). Tryptophan hydroxylase polymorphisms in suicide victims. Psychiatric Genetics 10, 13-17.
13. Berridge MJ, Downes CP, Hanley MR (1989). Neural and developmental actions of lithium: a unifying hypothesis. Cell 59, 411-419.
14. Bielski RJ, Friedel RO (1976). Prediction of tricyclic antidepressant response: a critical review. Archives of General Psychiatry 33, 1479-1489.
15. Blier P, de Montigny C (1994). Current advances and trends in the treatment of depression. Trends in Pharmacological Sciences 15, 220-226.
16. Brunn TG, Ewald H (1999). Selection bias of susceptibility genes possible when using parent offspring trios in genetic association studies. Molecular Psychiatry 4, 415-416.
17. 2+ valproate in cultured cerebellar neurons. Functional Neurology 10, 121-130.
18. Catalano M (In Press). Beyond the receptors: functional gene-linked polymorphic regions and neurotransmitter metabolism in a pharmacogenetic perspective. In: Lerer B (Ed.), Pharmacogenetics of Psychotropic Drugs. Cambridge: Cambridge University Press.
19. Cavazzoni P, Alda M, Turecki G, Rouleau G, Grof E, Martin R, Duffy A, Grof P (1996). Lithium-responsive affective disorders: no association with the tyrosine hydroxylase gene. Psychiatric Research 64, 91-96.
20. Chakravarti A (1999). Population genetics - making sense out of sequence. Nature Genetics 21, 56-60.
21. Chang FM, Kidd JR, Livak KJ, Pakstis AJ, Kidd KK (1996). The world-wide distribution of allele frequencies at the human dopamine D4 receptor locus. Human Genetics 98, 91-101.
22. Chen G, Huang LD, Zeng WZ, Manji HK (2001). Mood stabilizers regulate cytoprotective and mRNA-binding proteins in the brain: long-term effects on cell survival and transcript stability. International Journal of Neuropsychopharmacology 4, 47-64.
23. Collins A, Lonjou C, Morton NE (1999). Genetic epidemiology of single-nucleotide polymorphisms. Proceedings of the National Academy of Sciences USA 96, 15173-15177.
24. Coryell W, Akiskal H, Leon AC, Turvey C, Solomon D, Endicott J (2000). Family history and symptom levels during treatment for bipolar I affective disorder. Biological Psychiatry 47, 1034-1042.
25. Craddock N, Jones I (1999). Genetics of bipolar disorder. Journal of Medical Genetics 36, 585-594.
26. Cusin C, Serretti A, Zanardi R, Lattuada E, Rossini D, Lilli R, Lorenzi C, Smeraldi E (2002). Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms on SSRI antidepressant activity. International Journal of Neuropsychopharmacology 5, 27-36.
27. Del Zompo M, Ardau R, Palmas MA, Bocchetta A, Reina A, Piccardi MP (1999). Lithium response: association study with two candidate genes. Molecular Psychiatry 4, 66-67.
28. Detera-Wadleigh SD (2001). Lithium-related genetics of bipolar disorder. Annals of Medicine 33, 272-285.
29. Devlin B, Roeder K (1999). Genomic control for association studies. Biometrics 55, 997-1004.
30. Dratcu L, Calil HM (1989). The dexamethasone suppression test: its relationship to diagnoses, severity of depression and response to treatment. Progress in Neuropsychopharmacology and Biological Psychiatry 13, 99-117.
31. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, Arnold K, Ruano G, Liggett SB (2000). Complex promoter and coding region b2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proceedings of the National Academy of Sciences USA 97, 10483-10488.
32. Duffy A, Turecki G, Grof P, Cavazzoni P, Grof E, Joober R, Ahrens B, Berghofer A, Muller-Oerlinghausen B, Dvorakova M, Libigerova E, Vojtechovsky M, Zvolsky P, Nilsson A, Licht RW, Rasmussen NA, Schou M, Vestergaard P, Holzinger A, Schumann C, Thau K, Rouleau GA, Alda M (2000). Association and linkage studies of candidate genes involved in GABAergic neurotransmission in lithium responsive bipolar disorder. Journal of Psychiatry and Neuroscience 25, 353-358.
33. Duman RS, Heninger GR, Nestler EJ (1997). A molecular and cellular theory of depression. Archives of General Psychiatry 54, 597-606.
34. Duman RS, Malberg J, Nakagawa S, D'Sa C (2000). Neuronal plasticity and survival in mood disorders. Biological Psychiatry 48, 713-714.
35. Ehlers CL, Havstad JW, Kupfer DJ (1996). Estimation of the time course of slow-wave sleep over the night in depressed patients: effects of clomipramine and clinical response. Biological Psychiatry 39, 171-181.
36. Franchini L, Serretti A, Gasperini M, Smeraldi E (1998). Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. Journal of Psychiatric Research 32, 255-259.
37. Furlong RA, Ho L, Rubinsztein JS, Walsh C, Paykel ES, Rubinsztein DC (1998). No association of the tryptophan hydroxylase gene with bipolar affective disorder, unipolar affective disorder, or suicidal behaviour in major affective disorder. American Journal of Medical Genetics 81, 245-247.
38. Furlong RA, Ho L, Rubinsztein JS, Walsh C, Paykel ES, Rubinsztein DC (1999). Analysis of the monoamine oxidase A (MAOA) gene in bipolar affective disorder by association studies, meta-analyses, and sequencing of the promoter. American Journal of Medical Genetics 88, 398-406.
39. Garrod AE (1909). Inborn Errors of Metabolism. Oxford: Oxford University Press.
40. Garrod AE (1902). The incidence of alcaptonuria: a study in chemical individuality. Lancet 2, 1616-1620.
41. Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB, Shea MT, Imber SD, Sotsky SM, Watkins JT (1993). Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. Archives of General Psychiatry 50, 739-750.
42. Goodwin FK (1993). Predictors of antidepressant response. Bulletin of the Menninger Clinic 57, 146-160.
43. Grof P, Alda M, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M (2000). Treatment response in the relatives of lithium responders? International Journal of Neuropsychopharmacology 3 (Suppl. 1), 339.
44. Grof P, Alda M, Grof E, Zvolsky P, Walsh M (1994). Lithium response and genetics of affective disorders. Journal of Affective Disorders 32, 85-95.
45. Hoehe MR, Wendel B, Grunewald I, Chiaroni P, Levy N, Marris-Rosendahal D, Macher JP, Sander T, Crocq MA (1998). Serotonin transporter (5HTT) gene polymorphisms are not associated with susceptibility to mood disorders. American Journal of Medical Genetics 81, 1-3.
46. Horwath E, Weissman MM (1995). Epidemiology of depression and anxiety disorders. In: Tsuang MT, Tohen M, Zahner GEP (Eds.), Textbook in Psychiatric Epidemology (pp. 317-344). New York: Wiley-Liss.
47. International SNP Map Working Group (2001). A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409, 928-933.
48. Johnston-Wilson NL, Bouton CMLS, Pevsner J, Breen JJ, Torrey EF, Yolken RH, The Stanley Neurovirology Working Group (2001). Emerging technologies for large-scale screening of human tissues and fluids in the study of severe psychiatric disease. International Journal of Neuropsychopharmacology 4, 83-92.
49. Jope RS (1999). Anti-bipolar therapy: mechanism of action of lithium. Molecular Psychiatry 4, 117-128.
50. Joyce PR, Paykel ES (1989). Predictors of drug response in depression. Archives of General Psychiatry 46, 89-99.
51. Kato T (2001). Molecular genetics of bipolar disorder. Neuroscience Research 40, 105-113.
52. Kim KD, Lim SW, Lee S, En Sohn S, Kim S, Gyu Hahn C, Carroll BJ (2000). Serotonin transporter gene polymorphism and antidepressant response. NeuroReport 11, 215-219.
53. Kirov G, Jones I, McCandless F, Craddock N, Owen MJ (1998). Family-based association studies of bipolar disorder with candidate genes involved in dopamine neurotransmission: DBH, DAT1, COMT, DRD2, DRD3 and DRD5. Molecular Psychiatry 4, 558-565.
54. Kirov G, Norton N, Jones I, McCandless F, Craddock N, Owen MJ (1999). A functional polymorphism in the promoter of monoamine oxidase A gene and bipolar affective disorder. International Journal of Neuropsychopharmacology 2, 293-298.
55. Klein PS, Melton DA (1996). A molecular mechanism for the effect of lithium on development. Proceedings of the National Academy of Sciences USA 93, 8455-8459.
56. Krawezak M, Reiss J, Cooper DN (1992). The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Human Genetics 90, 41-54.
57. Lenox RH, Watson DGJP, Ellis J (1992). Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Research 570, 333-340.
58. Lerer B (Ed.) (2002). Pharmacogenetics of Psychotropic Drugs. Cambridge: Cambridge University Press.
59. Lerer B, Macciardi F, Segman RH, Adolfsson R, Blackwood D, Blairy S, Del-Favero J, Dikeos D, Kaneva E, Lilli R, Massat I, Milanova V, Muir W, Noethen M, Oruc L, Petrova T, Papadimitriou GN, Rietschel M, Serretti A, Souery D, Van Gestel S, Van Broeckhoven C, Mendlewicz JM (2001). Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder. Molecular Psychiatry 6, 579-585.
60. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R, Aschauer HN, McCreadie RG, Ohlraun S, Ferrier N, Masellis M, Verga M, Scharfetter J, Rietschel M, Lovlie R, Heresco Levy U, Kennedy JL, Steen VM, Macciardi F (2002). Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene ser9gly polymorphism. Neuropsychopharmacology.
61. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL (1996). Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274, 1527-1530.
62. Macciardi F (2002). Statistical approaches in psychopharmacogenetics. In: Lerer B (Ed.), Pharmacogenetics of Psychotropic Drugs. Cambridge: Cambridge University Press.
63. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977). Polymorphic hydroxylation of debrisoquine in man. Lancet 2, 584-586.
64. Malhotra AK, Goldman D (1999). Benefits and pitfalls encountered in psychiatric genetic association studies. Biological Psychiatry 45, 544-550.
65. Manji HK, Lenox RH (1999). Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic depressive illness. Biological Psychiatry 46, 1328-1351.
66. Manji HK, Lenox RH (2000). Signaling: cellular insights into the pathophysiology of bipolar disorder. Biological Psychiatry 48, 518-530.
67. Manji HK, Moore GJ, Chen G (1999). Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biological Psychiatry 46, 929-940.
68. Manji HK, Moore GJ, Chen G (2001). Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilisers. British Journal of Psychiatry 178, S107-S119.
69. McKnew DH, Cytryn L, Buchsbaum MS, Hamovit J, Lamour M, Rapoport JL, Gershon ES (1981). Lithium in children of lithium-responding parents. Psychiatric Research 4, 171-180.
70. Mendlewicz J, Fieve RR, Stallone F (1973). Relationship between the effectiveness of lithium therapy and family history. American Journal of Psychiatry 130, 1011-1013.
71. Mongeau R, Blier P, de Montigny C (1997). The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments. Brain Research Review 23, 145-195.
72. Motulsky A (1957). Drug reactions, enzymes and biochemical genetics. Journal of the American Medical Association 165, 835-837.
73. Mundo E, Walker M, Cate T, Macciardi F, Kennedy JL (2001). The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder. Archives of General Psychiatry 58, 539-544.
74. Naaby-Hansen S, Waterfield MD, Cramer R (2001). Proteomics - post-genomic cartography to understand gene function. Trends in Pharmacological Sciences 22, 376-384.
75. Nielsen DA, Virkkunen M, Lappalainen J, Eggert M, Brown GL, Long JC, Goldman D, Linnoila M (1998). A tryptophan hydroxylase gene marker for suicidality and alcoholism. Archives of General Psychiatry 55, 593-602.
76. Niswender CM, Hutchinson LK (2002). RNA processing regulation in psychiatric disorders: implications for interindividual variation in treatment. In: Lerer B (Ed.), Pharmacogenetics of Psychotropic Drugs. Cambridge: Cambridge University Press.
77. Nonaka S, Hough CJ, Chuang DM (1998). Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proceedings of the National Academy of Sciences USA 95, 2642-2647.
78. O'Reilly RL, Bouge L, Singh FM (1994). Pharmacogenetic response to antidepressant in a multicase family with affective disorder. Biological Psychiatry 36, 467-471.
79. Ozdemir V, Kahuba ADM, Basile VS, Kennedy JL (2002). Pharmacogenetics of psychotropic drug metabolism. In: Lerer B (Ed.) Pharmacogenetics of Psychotropic Drugs. Cambridge: Cambridge University Press.
80. Papolos DF, Veit S, Faedda GL, Saito T, Lachman HM (1998). Ultra-ultra rapid cycling bipolar disorder is associated with the low activity catecholamine-O-methyltransferase allele. Molecular Psychiatry 3, 346-349.
81. Pare CMB, Mack JW (1971). Differentiation of two genetically specific types of depression by the response to antidepressant drugs. Journal of Medical Genetics 8, 306-309.
82. Pare CMB, Rees L, Sainsbury MJ (1962). Differentiation of two genetically specific types of depression by the response to antidepressant. Lancet 2, 1340-1343.
83. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ (2000). Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23, 587-590.
84. Poolsup N, Li Wan Po A, Knight TL (2000). Pharmacogenetics and psychopharmacotherapy. Journal of Clinical Pharmacy and Therapeutics 25, 197-220.
85. Post RM, Berrettini W, Uhde TW, Kellner C (1984). Selective response to the anticonvulsant carbamazepine in manic-depressive illness: a case study. Journal of Clinical Psychopharmacology 4, 178-185.
86. Post RM, Frye MA, Denicoff KD, Leverich GS, Dunn RT, Osuch EA, Speer AM, Obrocea G, Jajodia K (2000). Emerging trends in the treatment of rapid cycling bipolar disorder: a selected review. Bipolar Disorder 2, 305-315.
87. Potash JB, DePaulo Jr. JR (2000). Searching high and low: a review of the genetics of bipolar disorder. Bipolar Disorders 2, 8-26.
88. Preisig M, Bellivier F, Fenton BT, Berney A, Courtet P, Hardy P, Golaz J, Leboyer M, Mallet J, Matthey ML, Mouthon D, Neidhart E, Nosten-Bertrand M, Stadelmann-Dubuis E, Guimon J, Ferrero F, Buresi C, Malafosse A (2000). Association between bipolar disorder and monoamine oxidase A gene polymorphisms: results of a multicenter study. American Journal of Psychiatry 157, 948-955.
89. Pritchard JK, Rosenberg NA (1999). Use of unlinked genetic markers to detect population stratification in association studies. American Journal of Human Genetics 65, 220-228.
90. Rees M, Norton N, Jones I, McCandless F, Scourfield J, Holmans P, Moorhead S, Feldman E, Sadler S, Cole T, Redman K, Farmer A, McGuffin P, Owen MJ, Craddock N (1997). Association studies of bipolar disorder at the human serotonin transporter gene (hSERT; 5HTT). Molecular Psychiatry 2, 398-402.
91. Reich DE, Cargill M, Bolk S, Ireland J, Sabeti PC, Richter DJ, Lavery T, Kouyoumjian R, Farhadian SF, Ward R, Lander ES (2001). Linkage disequilibrium in the human genome. Nature 411, 199-204.
92. Risch NJ (2000). Searching for genetic determinants in the new millennium. Nature 405, 847-856.
93. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, Moore JH (2001). Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. American Journal of Human Genetics 69, 138-147.
94. Rohlff C (2001). Proteomics in neuropsychiatric disorders. International Journal of Neuropsychopharmacology 4, 93-102.
95. Roose SP, Glassman AH, Attia E, Woodring S (1994). Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. American Journal of Psychiatry 15, 1735-1739.
96. Rosen RC, Lane RM, Menza M (1999). Effects of SSRIs on sexual function: a critical review. Journal of Clinical Psychopharmacology 19, 67-85.
97. Roses AD (2000). Pharmacogenetics and the practice of medicine. Nature 405, 857-865.
98. Sackeim HA (2001). The definition and meaning of treatment-resistant depression. Journal of Clinical Psychiatry 62, 10-17.
99. Schatzberg AF (1998). Noradrenergic versus serotonergic antidepressants: predictors of treatment response. Journal of Clinical Psychiatry 59, 15-18.
100. Schork NJ, Fallin D, Lanchbury S (2000). Single nucleotide polymorphisms and the future of genetic epidemiology. Clinical Genetics 58, 250-264.
101. Segman RH, Heresco-Levy U, Yakir A, Goltser T, Strous R, Greenberg D, Lerner A, Lerer B (2002). Interactive effect of cytochrome P-450 17α-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia. Biological Psychiatry.
102. Segman RH, Lerer B (2002). Age and the relationship of dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophrenia. Molecular Psychiatry 7, 137-139.
103. Serretti A, Franchini L, Gasperini M, Rampoldi R, Smeraldi E (1998a). Mode of inheritance in mood disorders families according to fluvoxamine response. Acta Psychiatrica Scandinavica 98, 443-450.
104. Serretti A, Lilli R, Lorenzi C, Franchini L, Di Bella D, Catalano M, Smeraldi E (1999a). Dopamine receptor D2 and D4 genes, GABA(A) alpha-1 subunit genes and response to lithium prophylaxis in mood disorders. Psychiatric Research 30, 7-19.
105. Serretti A, Lilli R, Lorenzi C, Franchini L, Smeraldi E (1998b). Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders. International Journal of Neuropsychopharmacology 1, 125-129.
106. Serretti A, Lilli R, Lorenzi C, Gasperini M, Smeraldi E (1999b). Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. Journal of Psychiatric Research 33, 371-377.
107. Serretti A, Lilli R, Mandelli L, Lorenzi C, Smeraldi E (2001c). Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics Journal 1, 71-77.
108. Serretti A, Lorenzi C, Lilli R, Smeraldi E (2000). Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. Journal of Psychiatric Research 34, 89-98.
109. Serretti A, Zanardi R, Cusin C, Rossini D, Lilli R, Lorenzi C, Lattuada E, Smeraldi E (In Press). No association between dopamine D2 and D4 receptor gene variants and antidepressant activity of two SSRIs. Psychiatric Research.
110. Serretti A, Zanardi R, Cusin C, Rossini D, Lorenzi C, Smeraldi E (2001b). Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. European Neuropsychopharmacology 11, 375-380.
111. Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E (2001a). Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Molecular Psychiatry 6, 586-592.
112. Shalom A, Darvasi A (2002). High-throughput single nucleotide polymorphism genotyping. In: Lerer B (Ed.), Pharmacogenetics of Psychotropic Drugs. Cambridge: Cambridge University Press.
113. Simpson S, Baldwin RC, Jackson A, Burns AS (1998). Is subcortical disease associated with a poor response to antidepressants? Neurological, neuropsychological and neuroradiological findings in late-life depression. Psychological Medicine 28, 1015-1026.
114. Sjoholt G, Gulbrandsen AK, Lovlie R, Berle JO, Molven A, Steen VM (2000). A human myo-inositol monophosphatase gene (IMPA2) localized in a putative susceptibility region for bipolar disorder on chromosome 18p11.2: genomic structure and polymorphism screening in manic-depressive patients. Molecular Psychiatry 5, 172-180.
115. Smeraldi E, Petroccione A, Gasperini M, Macciardi F, Orsini A, Kidd KK (1984). Outcomes on lithium treatment as a tool for genetic studies in affective disorders. Journal of Affective Disorders 6, 139-151.
116. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M (1998). Polymorphism within the serotonin transporter and antidepressant efficacy of fluvoxamine. Molecular Psychiatry 3, 508-511.
117. Sotsky SM, Glass DR, Shea MT, Pilkonis PA, Collins JF, Elkin I, Watkins JT, Imber SD, Leber WR, Moyer J, Oliveri, ME (1991). Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program. American Journal of Psychiatry 148, 997-1008.
118. Steen VM, Lovlie R, Osher Y, Belmaker RH, Berle JO, Gulbrandsen AK (1998). The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness. Pharmacogenetics 8, 259-268.
119. Steimer W, Muller B, Leucht S, Kissling W (2001). Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clinica Chimica Acta 308, 33-41.
120. Strakhova MI, Skolnick P (2001). Can 'differential display' methodologies make an impact on biological psychiatry? International Journal of Neuropsychopharmacology 4, 75-82.
121. Tohen M, Goodwin FK (1995). Epidemiology of bipolar disorder. In: Tsuang MT, Tohen M, Zahner GEP (Eds.), Textbook in Psychiatric Epidemiology (pp. 301-315). New York: Wiley-Liss.
122. Turecki G, Grof P, Cavazzoni P, Duffy A, Grof E, Ahrens B, Berghofer A, Muller-Oerlinghausen B, Dvorakova M, Libigerova E, Vojtechovsky M, Zvolsky P, Joober R, Nilsson A, Prochazka H, Licht RW, Rasmussen NA, Schou M, Vestergaard P, Holzinger A, Schumann C, Thau K, Rouleau GA, Alda M (1998). Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder. Molecular Psychiatry 3, 534-538.
123. Turecki G, Grof P, Cavazzoni P, Duffy A, Grof E, Ahrens B, Berghofer A, Muller-Oerlinghausen B, Dvorakova M, Libigerova E, Vojtechovsky M, Zvolsky P, Joober R, Nilsson A, Prochazka H, Licht RW, Rasmussen NA, Schou M, Vestergaard P, Holzinger A, Schumann C, Thau K, Rouleau GA, Alda M (1999a). MAOA: association and linkage studies with lithium responsive bipolar disorder. Psychiatric Genetics 9, 13-16.
124. Turecki G, Grof P, Cavazzoni P, Duffy A, Grof E, Martin R, Joober R, Rouleau GA, Alda M (1999b). Lithium responsive bipolar disorder, unilineality, and chromosome 18: A linkage study. American Journal of Medical Genetics (Neuropsychiatric Genetics) 88, 411-415.
125. Turecki G, Grof P, Grof E, D'Souza V, Lebuis L, Marineau C, Cavazzoni P, Duffy A, B'tard C, Zvolsky Pý, Brewer C, Hudson TJ, Rouleau GA, Alda M (2001). Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. Molecular Psychiatry 6, 570-578.
126. Veenstra-Vander Weele J, Anderson GM, Cook Jr. EH (2000). Pharmacogenetics and the serotonin system: initial studies and future directions. European Journal of Pharmacology 410, 165-181.
127. Vogel F (1959). Modern problems of human genetics. Ergebn inn Kinderheilk 12, 52-125.
128. Wang JF, Bown CD, Chen B, Young LT (2001). Identification of mood stabilizer-regulated genes by differential-display PCR. International Journal of Neuropsychopharmacology 4, 65-74.
129. Weiss KM, Terwilliger JD (2000). How many diseases does it take to map a gene with SNPs? Nature Genetics 26, 151-157.
130. Williams J, Spurlock G, Holmans P, Mant R, Murphy K, Jones L, Cardno A, Asherson P, Blackwood D, Muir W, Meszaros K, Aschauer H, Mallet J, Laurent C, Pekkarinen P, Seppala J, Stefanis CN, Papadimitriou GN, Macciardi F, Verga M, Pato C, Azevedo H, Crocq M-A, Gurling H, Kalsi G, Curtis D, McGuffin P, Owen MJ (1998). A metanalysis and transmission disequilibrium study of association between the dopamine D3 receptor gene and schizophrenia. Molecular Psychiatry 3, 141-149.
131. Yoshikawa T, Padigaru M, Karkera JD, Sharma M, Berrettini WH, Esterling LE, Detera-Wadleigh SD (2000). Genomic structure and novel variants of myo-inositol monophosphatase (IMPA2). Molecular Psychiatry 5, 165-171.
132. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E (2000). Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. Journal of Clinical Psychopharmacology 20, 105-107.
133. Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, Dotoli D, Smeraldi E (2001). Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biological Psychiatry 50, 323-330.
134. Zill P, Baghai TC, Zwanzger P, Schule C, Minov C, Riedel M, Neumeier K, Rupprecht R, Bondy B (2000). Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. NeuroReport 11, 1893-1897.